Diabetes News

Researchers found that women with hypertension who followed a very low-calorie ketogenic diet had lower systolic and diastolic blood pressure at 6 months than those who participated in intermittent fasting or had no dietary restrictions.

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, according to data from a cohort study published in the Journal of Diabetes and Its Complications.

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns about health care infrastructure and access to treatment for people in those regions.

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated insulin delivery system, according to findings from the SECURE-T2D trial.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health issues, recent data suggest they may improve brain health.

Sodium-glucose cotransporter 2, or SGLT2, inhibitors may be more cardioprotective for older adults, whereas glucagon-like peptide-1 receptor agonists may confer greater HbA1c reductions in that population, according to a systematic review and meta-analysis.

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers reported.

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean delivery, researchers reported.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy, researchers reported.